Lv1
60 积分 2021-05-14 加入
A phase III trial of adjuvant ribociclib plus endocrine therapy vs endocrine therapy alone in patients with HR+/HER2− early breast cancer: final invasive disease–free survival results from the NATALEE trial
2天前
已完结
Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
2天前
已完结
The mitochondrial ADP/ATP carrier (SLC25 family): Pathological implications of its dysfunction
3个月前
已完结
Significance of the mitochondrial thioredoxin reductase in cancer cells: An update on role, targets and inhibitors
3个月前
已完结
Bone-modifying agents for reducing bone loss in women with early and locally advanced breast cancer: a network meta-analysis
4个月前
已完结
Tumor-associated macrophages restrict CD8+ T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment
4个月前
已完结
Capivasertib and fulvestrant for patients with hormone receptor-positive, HER2-negative advanced breast cancer (CAPItello-291): patient-reported outcomes from a phase 3, randomised, double-blind, placebo-controlled trial
5个月前
已完结
Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor-positive breast cancer
5个月前
已完结
Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?
5个月前
已完结
Brain ischemia causes systemic Notch1 activity in endothelial cells to drive atherosclerosis
8个月前
已完结
口腔膜剂的研发与评价
1年前
已采纳
皖公网安备34019202002308
